IP Library Granted Patent US 9,347,098
Granted Patent B2
US 9,347,098 · App. 14/562,922 · Granted May 24, 2016

Reaction mixtures for quantitative amplification and detection over a wide dynamic range

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,347,098
App. No.
14/562,922
Granted
May 24, 2016
Kind
B2
Abstract

Disclosed are compositions and methods for making differentiable amplicon species at unequal ratios using a single amplification system in a single vessel. The number of differentiable amplicons and their ratios to one another are chosen to span the required linear dynamic range for the amplification reaction and to accommodate limitations of the measuring system used to determine the amount of amplicon generated. Unequal amounts of distinguishable amplicon species are generated by providing unequal amounts of one or more amplification reaction components (e.g., distinguishable amplification oligomers, natural and unnatural NTP in an NTP mix, or the like). The amount of target nucleic acid present in a test sample is determined using the linear detection range generated from detection of one or more amplicon species having an amount within the dynamic range of detection.

Claims (16)

1. A nucleic acid amplification reaction mixture comprising at least two primers and at least two probes, wherein:

(a) the at least two primers hybridize to the same strand of a target nucleic acid sequence but each primer hybridizes to a distinct nucleotide sequence on the strand,

wherein each primer is present in the reaction mixture at a different amount P x , where x is an integer between 1 and the number of primers in the mixture, and wherein the at least two primers comprise a first inner primer and a second outer primer;

(b) each primer is capable of simultaneously and independently producing one of at least two amplicons from the target nucleic acid sequence under amplification conditions,

wherein for each amplicon, a number of copies A x is capable of being produced, wherein each A x differs by at least two orders of magnitude, and

wherein the at least two amplicons comprise a first amplicon capable of being produced from the first inner primer and a second amplicon capable of being produced from the second outer primer, wherein the first amplicon is shorter than the second amplicon;

(c) the at least two amplicons are detectable by hybridization with the at least two probes, wherein one of the at least two probes is specific to a nucleotide sequence common to both the first and second amplicons and another of the at least two probes is specific to a nucleotide sequence contained within the second amplicon but not within the first amplicon, and each probe is detectable within a detection range C x(a) to C x(b) ,

wherein C x(a) is the minimum detectable number of copies of amplicon and C x(b) is the maximum detectable number of copies of amplicon for probe x,

wherein for each probe, C x+1(a) is greater than C x(a) and C x+1(b) is greater than C x(b) such that the at least two probes together are detectable across a dynamic range of from about 10 3 to 10 7 , wherein for each amplicon-probe combination, A x is between C x(a) and C x(b) , and wherein the at least two probes are capable of producing distinguishable detection signals.

2. The reaction mixture of claim 1 , wherein the reaction mixture further comprises a promoter-primer which operates in a direction opposite the first inner and second outer primers.

3. The reaction mixture of claim 1 , wherein the number of copies of each amplicon A x differs by at least three orders of magnitude.

4. The reaction mixture of claim 1 , wherein the number of copies of each amplicon A x differs by at least four orders of magnitude.

5. The reaction mixture of claim 1 , wherein the amount of each primer differs by at least two orders of magnitude.

6. The reaction mixture of claim 1 , wherein the at least two probes are acridinium ester probes.

7. The reaction mixture of claim 1 , wherein the at least two probes are HICS probes.

8. The reaction mixture of claim 1 , wherein the dynamic range is from about 10 4 to 10 6 .

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2016
From: KACIAN, DANIEL L.; BROWNE, KENNETH A.
To: GEN-PROBE INCORPORATED
Reel/Frame 038334/0752 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 034784 0590 Recorded Jul 17, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 036127/0001 →
SECURITY INTEREST Recorded Jan 22, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK, USA
Reel/Frame 034784/0590 →